Dexelvucitabine

Dexelvucitabine

Names
IUPAC name 2′,3′-Didehydro-2′,3′-dideoxy-5-fluorocytidine
Systematic IUPAC name 4-Amino-5-fluoro-1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-1-yl]pyrimidin-2(1H)-one
Other names Reverset
Identifiers
CAS Number	134379-77-4 Y
3D model ( JSmol )	Interactive image
ChEMBL	ChEMBL109831 N
ChemSpider	58498 N
KEGG	D03981 Y
PubChem CID	64973
UNII	KU8SPJ271W Y
CompTox Dashboard (EPA)	DTXSID20158678
InChI InChI=1S/C9H10FN3O3/c10-6-3-13(9(15)12-8(6)11)7-2-1-5(4-14)16-7/h1-3,5,7,14H,4H2,(H2,11,12,15)/t5-,7+/m0/s1 N Key: HSBKFSPNDWWPSL-CAHLUQPWSA-N N InChI=1/C9H10FN3O3/c10-6-3-13(9(15)12-8(6)11)7-2-1-5(4-14)16-7/h1-3,5,7,14H,4H2,(H2,11,12,15)/t5-,7+/m0/s1 Key: HSBKFSPNDWWPSL-CAHLUQPWBD
SMILES F\C1=C\N(C(=O)\N=C1\N)[C@@H]/2O[C@@H](\C=C\2)CO
Properties
Chemical formula	C9H10FN3O3
Molar mass	227.195 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). N verify (what is YN ?) Infobox references

Dexelvucitabine is a failed experimental agent for the management of human immunodeficiency virus infection. It is a cytidine nucleoside analog and nucleoside reverse transcriptase inhibitor.^[1] that inhibits HIV-1 replication in vitro. During phase II clinical trials there was some indication of a decreased mean viral load in patients with infected human immunodeficiency virus.^[2][3]

On April 3, 2006, Pharmasset and Incyte, the pharmaceutical companies developing dexelvucitabine, announced the decision to cease further trials and development of the drug due to an increased incidence of grade 4 hyperlipasemia (an excess of the pancreatic enzyme lipase in the bloodstream) in a phase II trial.^[1][4]

References